A new, integrated data analysis of available studies concluded that drugs used to treat attention deficit hyperactivity disorder (ADHD) can successfully treat key aspects of Alzheimer’s disease. The study was published July 5, 2022 in the Journal of Neurology, Neurosurgery and Psychiatry.
According to the researchers, the results of the study indicate that clinical trials of noradrenergic drugs, including antidepressants and treatments for hypertension and ADHD, are now feasible.
Noradrenaline, a neurotransmitter also known as norepinephrine, is secreted by a specialized network of noradrenergic neurons.
Disruption of the noradrenergic system occurs early in Alzheimer’s disease and contributes to the characteristic cognitive and neuropsychiatric symptoms of the condition, suggesting that the noradrenergic system may be a viable target for drug therapy.
As a result, researchers used noradrenergic drugs such as methylphenidate, atomoxetine, and guanfacine in clinical trials published between 1980 and 2021 for cognitive and/or neuropsychiatric symptoms in people with neurodegenerative disorders. We searched for clinical trials that could potentially improve
A total of 19 randomized controlled trials focused on Alzheimer’s disease and mild cognitive impairment were included and included 1811 patients. Of these tests, 6 were rated as ‘good’, 7 as ‘average’, and 6 as ‘bad’.
We pooled the results of 10 of these trials in 1300 patients for overall cognition (orientation/attention, memory, verbal fluency, language and spatiotemporal competence).
This network is essential for many cognitive processes, such as arousal and attention, memory, learning, action preparation, and inhibition of inappropriate behavior.
Disruption of the noradrenergic system occurs early in Alzheimer’s disease and contributes to the characteristic cognitive and neuropsychiatric symptoms of the condition, suggesting that the noradrenergic system may be a viable target for drug therapy.
As a result, researchers used noradrenergic drugs such as methylphenidate, atomoxetine, and guanfacine in clinical trials published between 1980 and 2021 for cognitive and/or neuropsychiatric symptoms in people with neurodegenerative disorders. We searched for clinical trials that could potentially improve
A total of 19 randomized controlled trials focused on Alzheimer’s disease and mild cognitive impairment were included and included 1811 patients. Of these tests, 6 were rated as ‘good’, 7 as ‘average’, and 6 as ‘bad’.
We pooled the results of 10 of these trials in 1300 patients for overall cognition (orientation/attention, memory, verbal fluency, language and spatiotemporal competence).
“Good Evidence” That ADHD Drugs May Also Successfully Treat Alzheimer’s Dementia – https://t.co/44ccgtRAuP
— Thaddeus Arjuna. Aspiring Scribe, w/ tidy typos (@ThaddeusArjuna) July 10, 2022